0	9	Transient	transient	JJ
10	34	pseudo-hypoaldosteronism	pseudo-hypoaldosteronism	NN
35	44	following	follow	VBG
45	54	resection	resection	NN
55	57	of	of	IN
58	61	the	the	DT
62	67	ileum	ileum	NN
67	68	:	:	:
69	75	normal	normal	JJ
76	81	level	level	NN
82	84	of	of	IN
85	96	lymphocytic	lymphocytic	JJ
97	108	aldosterone	aldosterone	NN
109	118	receptors	receptor	NNS
119	126	outside	outside	IN
127	130	the	the	DT
131	136	acute	acute	JJ
137	142	phase	phase	NN
142	143	.	.	.

145	169	Pseudo-hypoaldosteronism	Pseudo-hypoaldosteronism	NNP
170	171	(	(	(
171	174	PHA	PHA	NNP
174	175	)	)	)
176	178	is	be	VBZ
179	182	due	due	JJ
183	185	to	to	TO
186	203	mineralocorticoid	mineralocorticoid	NN
204	214	resistance	resistance	NN
215	218	and	and	CC
219	228	manifests	manifest	VBZ
229	231	as	as	IN
232	244	hyponatremia	hyponatremia	NN
245	248	and	and	CC
249	261	hyperkalemia	hyperkalemia	NN
262	266	with	with	IN
267	276	increased	increase	VBN
277	283	plasma	plasma	NN
284	295	aldosterone	aldosterone	NN
296	302	levels	level	NNS
302	303	.	.	.

304	306	It	it	PRP
307	310	may	may	MD
311	313	be	be	VB
314	322	familial	familial	JJ
323	325	or	or	CC
326	335	secondary	secondary	JJ
336	338	to	to	TO
339	347	abnormal	abnormal	JJ
348	353	renal	renal	JJ
354	360	sodium	sodium	NN
361	369	handling	handling	NN
369	370	.	.	.

371	373	We	we	PRP
374	380	report	report	VBP
381	384	the	the	DT
385	389	case	case	NN
390	392	of	of	IN
393	394	a	a	DT
395	406	54-year-old	54-year-old	JJ
407	412	woman	woman	NN
413	417	with	with	IN
418	428	multifocal	multifocal	JJ
429	435	cancer	cancer	NN
436	438	of	of	IN
439	442	the	the	DT
443	448	colon	colon	NN
448	449	,	,	,
450	453	who	who	WP
454	463	developed	develop	VBD
464	467	PHA	PHA	NNP
468	473	after	after	IN
474	482	subtotal	subtotal	JJ
483	492	colectomy	colectomy	NN
492	493	,	,	,
494	499	ileal	ileal	JJ
500	509	resection	resection	NN
510	513	and	and	CC
514	525	jejunostomy	jejunostomy	NN
525	526	.	.	.

527	530	She	she	PRP
531	534	was	be	VBD
535	542	treated	treat	VBN
543	547	with	with	IN
548	549	6	6	CD
550	551	g	g	NN
552	554	of	of	IN
555	559	salt	salt	NN
560	565	daily	daily	JJ
566	568	to	to	TO
569	576	prevent	prevent	VB
577	588	dehydration	dehydration	NN
588	589	,	,	,
590	595	which	which	WDT
596	599	she	she	PRP
600	607	stopped	stop	VBD
608	615	herself	herself	PRP
616	623	because	because	IN
624	626	of	of	IN
627	634	reduced	reduce	VBN
635	640	fecal	fecal	JJ
641	647	losses	loss	NNS
647	648	.	.	.

649	652	One	one	CD
653	658	month	month	NN
659	664	later	later	RB
665	668	she	she	PRP
669	672	was	be	VBD
673	681	admitted	admit	VBN
682	686	with	with	IN
687	692	signs	sign	NNS
693	695	of	of	IN
696	701	acute	acute	JJ
702	709	adrenal	adrenal	JJ
710	717	failure	failure	NN
717	718	,	,	,
719	723	i.e.	i.e.	FW
724	731	fatigue	fatigue	NN
731	732	,	,	,
733	739	severe	severe	JJ
740	746	nausea	nausea	NN
746	747	,	,	,
748	753	blood	blood	NN
754	762	pressure	pressure	NN
763	765	of	of	IN
766	771	80/60	80/60	CD
772	776	mmHg	mmhg	NN
776	777	,	,	,
778	791	extracellular	extracellular	JJ
792	803	dehydration	dehydration	NN
803	804	,	,	,
805	817	hyponatremia	hyponatremia	NN
818	819	(	(	(
819	822	118	118	CD
823	829	mmol/l	mmol/l	NN
829	830	)	)	)
830	831	;	;	:
832	844	hyperkalemia	hyperkalemia	NN
845	846	(	(	(
846	849	7.6	7.6	CD
850	856	mmol/l	mmol/l	NN
856	857	)	)	)
857	858	,	,	,
859	868	increased	increase	VBN
869	874	blood	blood	NN
875	879	urea	urea	NN
880	888	nitrogen	nitrogen	NN
889	890	(	(	(
890	893	BUN	BUN	NNP
893	894	)	)	)
895	896	(	(	(
896	899	200	200	CD
900	905	mg/dl	mg/dl	NN
905	906	)	)	)
907	910	and	and	CC
911	924	creatininemia	creatininemia	NN
925	926	(	(	(
926	929	2.5	2.5	CD
930	935	mg/dl	mg/dl	NN
935	936	)	)	)
936	937	,	,	,
938	941	and	and	CC
942	951	decreased	decrease	VBN
952	958	plasma	plasma	NN
959	971	bicarbonates	bicarbonate	NNS
972	977	level	level	NN
978	979	(	(	(
979	984	HCO3-	HCO3-	NNP
984	985	:	:	:
986	988	16	16	CD
989	995	mmol/l	mmol/l	NN
995	996	;	;	:
997	998	N	N	NNP
998	999	:	:	:
1000	1005	27-30	27-30	CD
1005	1006	)	)	)
1006	1007	.	.	.

1008	1015	However	however	RB
1015	1016	,	,	,
1017	1020	the	the	DT
1021	1027	plasma	plasma	NN
1028	1036	cortisol	cortisol	NN
1037	1040	was	be	VBD
1041	1045	high	high	JJ
1046	1047	(	(	(
1047	1049	66	66	CD
1050	1060	microg/100	microg/100	NN
1061	1063	ml	ml	NN
1064	1066	at	at	IN
1067	1072	10:00	10:00	CD
1073	1074	h	h	NN
1074	1075	;	;	:
1076	1077	N	N	NNP
1077	1078	:	:	:
1079	1083	8-15	8-15	CD
1083	1084	)	)	)
1085	1088	and	and	CC
1089	1092	the	the	DT
1093	1097	ACTH	acth	NN
1098	1101	was	be	VBD
1102	1108	normal	normal	JJ
1109	1110	(	(	(
1110	1112	13	13	CD
1113	1118	pg/ml	pg/ml	NN
1118	1119	,	,	,
1120	1121	N	N	NNP
1121	1122	:	:	:
1123	1128	10-60	10-60	CD
1128	1129	)	)	)
1129	1130	;	;	:
1131	1136	there	there	EX
1137	1140	was	be	VBD
1141	1142	a	a	DT
1143	1149	marked	marked	JJ
1150	1158	increase	increase	NN
1159	1161	in	in	IN
1162	1168	plasma	plasma	NN
1169	1174	renin	renin	NN
1175	1183	activity	activity	NN
1184	1185	(	(	(
1185	1188	>37	>37	CD
1189	1196	ng/ml/h	ng/ml/h	NN
1196	1197	;	;	:
1198	1199	N	N	NNP
1200	1206	supine	supine	NN
1207	1209	<3	<3	NN
1209	1210	)	)	)
1210	1211	,	,	,
1212	1218	active	active	JJ
1219	1224	renin	renin	NN
1225	1226	(	(	(
1226	1229	869	869	CD
1230	1235	pg/ml	pg/ml	NN
1235	1236	;	;	:
1237	1238	N	N	NNP
1239	1245	supine	supine	NN
1245	1246	:	:	:
1247	1252	1.120	1.120	CD
1252	1253	)	)	)
1253	1254	,	,	,
1255	1266	aldosterone	aldosterone	NN
1267	1268	(	(	(
1268	1273	>2000	>2000	CD
1274	1279	pg/ml	pg/ml	NN
1279	1280	;	;	:
1281	1282	N	N	NNP
1283	1289	supine	supine	NN
1290	1294	<150	<150	NN
1294	1295	)	)	)
1296	1299	and	and	CC
1300	1306	plasma	plasma	NN
1307	1310	AVP	AVP	NNP
1311	1312	(	(	(
1312	1314	20	20	CD
1315	1321	pmol/l	pmol/l	NN
1321	1322	;	;	:
1323	1324	N	N	NNP
1324	1325	:	:	:
1326	1333	0.5-2.5	0.5-2.5	CD
1333	1334	)	)	)
1334	1335	.	.	.

1336	1339	The	the	DT
1340	1346	plasma	plasma	NN
1347	1350	ANH	ANH	NNP
1351	1356	level	level	NN
1357	1360	was	be	VBD
1361	1363	38	38	CD
1364	1370	pmol/l	pmol/l	NN
1371	1372	(	(	(
1372	1373	N	N	NNP
1374	1380	supine	supine	NN
1380	1381	:	:	:
1382	1386	5-25	5-25	CD
1386	1387	)	)	)
1387	1388	.	.	.

1389	1390	A	a	DT
1391	1398	urinary	urinary	JJ
1399	1411	steroidogram	steroidogram	NN
1412	1420	resulted	result	VBD
1421	1423	in	in	IN
1424	1430	highly	highly	RB
1431	1439	elevated	elevated	JJ
1440	1458	tetrahydrocortisol	tetrahydrocortisol	NN
1459	1460	(	(	(
1460	1463	THF	THF	NNP
1463	1464	:	:	:
1465	1469	13.3	13.3	CD
1470	1476	mg/24h	mg/24h	NN
1476	1477	;	;	:
1478	1479	N	N	NNP
1479	1480	:	:	:
1481	1490	1.4+/-0.8	1.4+/-0.8	CD
1490	1491	)	)	)
1492	1496	with	with	IN
1497	1499	no	no	DT
1500	1508	increase	increase	NN
1509	1511	in	in	IN
1512	1531	tetrahydrocortisone	tetrahydrocortisone	NN
1532	1533	(	(	(
1533	1536	THE	the	DT
1536	1537	:	:	:
1538	1542	3.16	3.16	CD
1543	1549	mg/24h	mg/24h	NN
1549	1550	;	;	:
1551	1552	N	N	NNP
1552	1553	:	:	:
1554	1563	2.7+/-2.0	2.7+/-2.0	CD
1563	1564	)	)	)
1565	1574	excretion	excretion	NN
1574	1575	,	,	,
1576	1579	and	and	CC
1580	1584	with	with	IN
1585	1588	low	low	JJ
1589	1596	THE/THF	THE/THF	NNP
1597	1598	(	(	(
1598	1602	0.24	0.24	CD
1602	1603	;	;	:
1604	1605	N	N	NNP
1605	1606	:	:	:
1607	1618	1.87+/-0.36	1.87+/-0.36	CD
1618	1619	)	)	)
1620	1623	and	and	CC
1624	1629	alpha	alpha	NN
1630	1637	THF/THF	thf/thf	NN
1638	1639	(	(	(
1639	1643	0.35	0.35	CD
1643	1644	;	;	:
1645	1646	N	N	NNP
1646	1647	:	:	:
1648	1659	0.92+/-0.42	0.92+/-0.42	CD
1659	1660	)	)	)
1661	1667	ratios	ratio	NNS
1667	1668	.	.	.

1669	1672	The	the	DT
1673	1679	number	number	NN
1680	1682	of	of	IN
1683	1700	mineralocorticoid	mineralocorticoid	NN
1701	1710	receptors	receptor	NNS
1711	1713	in	in	IN
1714	1725	mononuclear	mononuclear	JJ
1726	1736	leukocytes	leukocyte	NNS
1737	1740	was	be	VBD
1741	1743	in	in	IN
1744	1747	the	the	DT
1748	1753	lower	low	JJR
1754	1760	normal	normal	JJ
1761	1766	range	range	NN
1767	1770	for	for	IN
1771	1774	age	age	NN
1774	1775	,	,	,
1776	1781	while	while	IN
1782	1785	the	the	DT
1786	1792	number	number	NN
1793	1795	of	of	IN
1796	1810	glucocorticoid	glucocorticoid	NN
1811	1820	receptors	receptor	NNS
1821	1824	was	be	VBD
1825	1832	reduced	reduce	VBN
1832	1833	.	.	.

1834	1845	Small-bowel	small-bowel	JJ
1846	1855	resection	resection	NN
1856	1858	in	in	IN
1859	1871	ileostomized	ileostomized	JJ
1872	1880	patients	patient	NNS
1881	1887	causes	cause	VBZ
1888	1897	excessive	excessive	JJ
1898	1903	fecal	fecal	JJ
1904	1910	sodium	sodium	NN
1911	1917	losses	loss	NNS
1918	1921	and	and	CC
1922	1929	results	result	VBZ
1930	1932	in	in	IN
1933	1940	chronic	chronic	JJ
1941	1947	sodium	sodium	NN
1948	1957	depletion	depletion	NN
1958	1962	with	with	IN
1963	1974	contraction	contraction	NN
1975	1977	of	of	IN
1978	1981	the	the	DT
1982	1988	plasma	plasma	NN
1989	1995	volume	volume	NN
1996	1999	and	and	CC
2000	2006	severe	severe	JJ
2007	2016	secondary	secondary	JJ
2017	2035	hyperaldosteronism	hyperaldosteronism	NN
2035	2036	.	.	.

2037	2049	Nevertheless	nevertheless	RB
2049	2050	,	,	,
2051	2055	this	this	DT
2056	2074	hyperaldosteronism	hyperaldosteronism	NN
2075	2078	may	may	MD
2079	2081	be	be	VB
2082	2092	associated	associate	VBN
2093	2097	with	with	IN
2098	2110	hyponatremia	hyponatremia	NN
2111	2114	and	and	CC
2115	2127	hyperkalemia	hyperkalemia	NN
2128	2138	suggesting	suggest	VBG
2139	2142	PHA	PHA	NNP
2143	2150	related	related	JJ
2151	2153	to	to	TO
2154	2157	the	the	DT
2158	2163	major	major	JJ
2164	2174	importance	importance	NN
2175	2177	of	of	IN
2178	2181	the	the	DT
2182	2187	colon	colon	NN
2188	2191	for	for	IN
2192	2195	the	the	DT
2196	2206	absorption	absorption	NN
2207	2209	of	of	IN
2210	2216	sodium	sodium	NN
2216	2217	.	.	.

2218	2220	In	in	IN
2221	2231	conclusion	conclusion	NN
2231	2232	,	,	,
2233	2237	this	this	DT
2238	2242	case	case	NN
2243	2249	report	report	NN
2250	2260	emphasizes	emphasize	VBZ
2261	2262	1	1	LS
2262	2263	)	)	)
2264	2267	the	the	DT
2268	2279	possibility	possibility	NN
2280	2282	of	of	IN
2283	2284	a	a	DT
2285	2293	syndrome	syndrome	NN
2294	2296	of	of	IN
2297	2305	acquired	acquire	VBN
2306	2309	PHA	PHA	NNP
2310	2314	with	with	IN
2315	2321	severe	severe	JJ
2322	2334	hyperkalemia	hyperkalemia	NN
2335	2340	after	after	IN
2341	2350	resection	resection	NN
2351	2353	of	of	IN
2354	2357	the	the	DT
2358	2363	ileum	ileum	NN
2364	2367	and	and	CC
2368	2373	colon	colon	NN
2374	2384	responding	respond	VBG
2385	2387	to	to	TO
2388	2392	oral	oral	JJ
2393	2397	salt	salt	NN
2398	2413	supplementation	supplementation	NN
2413	2414	;	;	:
2415	2416	2	2	LS
2416	2417	)	)	)
2418	2421	the	the	DT
2422	2427	major	major	JJ
2428	2436	increase	increase	NN
2437	2439	in	in	IN
2440	2443	AVP	AVP	NNP
2444	2447	and	and	CC
2448	2451	the	the	DT
2452	2457	small	small	JJ
2458	2466	increase	increase	NN
2467	2469	in	in	IN
2470	2473	ANH	ANH	NNP
2473	2474	;	;	:
2475	2476	3	3	LS
2476	2477	)	)	)
2478	2481	the	the	DT
2482	2488	strong	strong	JJ
2489	2497	increase	increase	NN
2498	2500	in	in	IN
2501	2508	urinary	urinary	JJ
2509	2512	THF	thf	NN
2513	2517	with	with	IN
2518	2521	low	low	JJ
2522	2529	THE/THF	the/thf	NN
2530	2533	and	and	CC
2534	2539	alpha	alpha	NN
2540	2547	THF/THF	thf/thf	NN
2548	2554	ratios	ratio	NNS
2554	2555	;	;	:
2556	2557	4	4	LS
2557	2558	)	)	)
2559	2562	the	the	DT
2563	2569	normal	normal	JJ
2570	2576	number	number	NN
2577	2579	of	of	IN
2580	2591	lymphocytic	lymphocytic	JJ
2592	2609	mineralocorticoid	mineralocorticoid	NN
2610	2619	receptors	receptor	NNS
2620	2627	outside	outside	IN
2628	2631	the	the	DT
2632	2637	acute	acute	JJ
2638	2645	episode	episode	NN
2645	2646	.	.	.